These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8560351)

  • 1. [Effects of cyclosporin A on various indices of cholestasis in kidney transplant recipients].
    Soresi M; Sparacino V; Pisciotta G; Bonfissuto G; Caputo F; Carroccio A; Calabrese S; Montalto G
    Minerva Urol Nefrol; 1995 Jun; 47(2):65-9. PubMed ID: 8560351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin A-mediated cholestasis in patients with chronic hepatitis after heart transplantation.
    Myara A; Cadranel JF; Dorent R; Lunel F; Bouvier E; Gerhardt M; Bernard B; Ghoussoub JJ; Cabrol A; Gandjbakhch I; Opolon P; Trivin F
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):267-71. PubMed ID: 8724029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
    Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered flow properties of blood and increased plasma fibrinogen in cyclosporin-treated renal allograft recipients.
    Linde T; Sandhagen B; Backman U; Fellström B
    Nephrol Dial Transplant; 1999 Jun; 14(6):1525-9. PubMed ID: 10383019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function and lipid metabolism in pregnant renal transplant recipients.
    Czajkowski K; Wójcicka-Bentyn J; Sieńko J; Grymowicz M; Smolarczyk R; Malinowska-Polubiec A; Romejko E
    Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):155-61. PubMed ID: 15140508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical parameters in chronic fascioliasis.
    El-Shazly AM; Azab MS; El-Beshbishi SN; Sakr TI; El-Fayoumy KN; El-Ghareeb AS; Hafez AO; El Sherbini ET
    J Egypt Soc Parasitol; 2008 Dec; 38(3):977-90. PubMed ID: 19209779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of preoperative biliary drainage on liver function changes in patients with malignant obstructive jaundice in the low bile duct before and after pancreaticoduodenectomy].
    Chen D; Liang LJ; Peng BG; Zhou Q; Li SQ; Tang D; Huang L; Huang JF
    Ai Zheng; 2008 Jan; 27(1):78-82. PubMed ID: 18184470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients.
    Ott R; Bussenius-Kammerer M; Reck T; Koch CA; Kissler H; Hohenberger W; Müller V
    Transpl Int; 2004 Jan; 17(1):39-43. PubMed ID: 14504723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on gingival overgrowth by cyclosporine A in renal transplants.
    Ciavarella D; Guiglia R; Campisi G; Di Cosola M; Di Liberto C; Sabatucci A; Escudero N; Bascones A; Lo Muzio L
    Med Oral Patol Oral Cir Bucal; 2007 Jan; 12(1):E19-25. PubMed ID: 17195822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac and vascular abnormalities in renal transplant patients: differential effects of cyclosporin and azathioprine.
    Galiatsou E; Morris ST; Jardine AG; Rodger RS; Watson MA; Elliott HL
    J Nephrol; 2000; 13(3):185-92. PubMed ID: 10928294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of biliary complications after heart transplantation.
    Peterseim DS; Pappas TN; Meyers CH; Shaeffer GS; Meyers WC; Van Trigt P
    J Heart Lung Transplant; 1995; 14(4):623-31. PubMed ID: 7578167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic gallstones and duration of cyclosporine use in kidney transplant recipients.
    Alberú J; Gatica M; Cachafeiro-Vilar M; Robles-Díaz G; Bezaury P; Paz-Pinedo F; Vargas-Vorácková F
    Rev Invest Clin; 2001; 53(5):396-400. PubMed ID: 11795104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
    Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin.
    Simic P; Gasparovic V; Skegro M; Stern-Padovan R
    Clin Drug Investig; 2006; 26(6):361-5. PubMed ID: 17163271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients.
    Schmidt LE; Rasmussen A; Kirkegaard P; Dalhoff K
    Transplantation; 2003 Jul; 76(2):358-63. PubMed ID: 12883193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus-induced cholestatic syndrome following pediatric liver transplantation and steroid-resistant graft rejection.
    Ganschow R; Albani J; Grabhorn E; Richter A; Burdelski M
    Pediatr Transplant; 2006 Mar; 10(2):220-4. PubMed ID: 16573611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: a cyclosporine A associated side effect.
    Stahl RA; Kanz L; Maier B; Schollmeyer P
    Clin Nephrol; 1986 May; 25(5):245-8. PubMed ID: 3521998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A-related Raynaud's phenomenon in a renal transplant recipient.
    Sharma AK; Sunil S; Rustom R; Bone JM; Hammad A; Bakran A; Sells RA
    Transpl Int; 2002 Oct; 15(9-10):517-8. PubMed ID: 12389086
    [No Abstract]   [Full Text] [Related]  

  • 19. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
    Deleuze S; Garrigue V; Delmas S; Chong G; Swarcz I; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2311-3. PubMed ID: 16980075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients.
    Pons JA; Ramírez P; Revilla-Nuin B; Pascual D; Baroja-Mazo A; Robles R; Sanchez-Bueno F; Martinez L; Parrilla P
    Clin Transplant; 2009; 23(3):329-36. PubMed ID: 19210687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.